Non small cell lung cancer diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(12 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Non small cell lung cancer}}
{{Non small cell lung cancer}}
{{CMG}}; {{AE}}{{Trusha}},{{MMF}}
{{CMG}}; {{AE}}{{Trusha}}, {{MMF}}


== Overview ==
== Overview ==
Line 32: Line 32:


  {{familytree/start |summary= Imaging Evaluation Algorithm Non-Small Cell Lung Cancer}}
  {{familytree/start |summary= Imaging Evaluation Algorithm Non-Small Cell Lung Cancer}}
{{familytree | | | | | | A02 | | | | | | A02=<div style="width: 10em; padding:0.2em;">'''Imaging approach'''<br> ❑ Suspected lung cancer</div>}}
{{familytree | | | | | | A02 | | | | | | A02=<div style="width: 10em; padding:0.2em;">'''Imaging approach'''<br> ❑ Suspected [[lung cancer]]</div>}}
{{familytree | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | Z01 | | | | | | | Z01=Chest X Ray normal?}}
{{familytree | | | | | | Z01 | | | | | | | Z01=[[Chest X Ray]] normal?}}
{{familytree | | | |,|-|-|^|-|-|.| | | | | }}
{{familytree | | | |,|-|-|^|-|-|.| | | | | }}
{{familytree | | | B01 | | | | B02 | | | B01=No|B02=Yes}}
{{familytree | | | B01 | | | | B02 | | | B01=No|B02=Yes}}
{{familytree | | | |!| | | | | |!| | | | | }}
{{familytree | | | |!| | | | | |!| | | | | }}
{{familytree | | | C01 | | | | C02 | | | | C01=<div style="width: 17em; padding:1em;text-align:left">'''Enhanced Computed Tomography (ECT), includes:''' <br>❑ Thorax <br>❑ Upper Abdomen<br> ❑ Low Neck<br></div>|C02=<div style="width: 15em; padding:1em;">'''Manage and observe'''</div>}}
{{familytree | | | C01 | | | | C02 | | | | C01=<div style="width: 17em; padding:1em;text-align:left">'''[[CT|Enhanced Computed Tomography (ECT)]], includes:''' <br>❑ Thorax <br>❑ Upper Abdomen<br> ❑ Low Neck<br></div>|C02=<div style="width: 15em; padding:1em;">'''Manage and observe'''</div>}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | C03 | | | | | | | | | | | |C03=<div style="width: 10em; padding:0.2em;">'''Imaging evaluation'''</div>}}
{{familytree | | | C03 | | | | | | | | | | | |C03=<div style="width: 10em; padding:0.2em;">'''Imaging evaluation'''</div>}}
{{familytree|boxstyle= border-top: 0px;| | | C04 | | | | | | | | | | | C04=<div style="width: 17em; padding:1em;text-align:left">'''Location'''<br> ❑ Central<br> ❑ Peripheral <br> ❑ Pleural lesion <br>'''Size''' <br>'''Lesion characteristics'''<br>  ❑ Margins (irregular/regular)<br>  ❑ Shape (spiculated/rounded)<br>'''Presence of cavitation'''<br>❑ Yes<br>❑ No<br>''' Type of adenopathy'''<br> ❑ Hiliar <br> ❑ Mediastinal <br></div>}}
{{familytree|boxstyle= border-top: 0px;| | | C04 | | | | | | | | | | | C04=<div style="width: 17em; padding:1em;text-align:left">'''Location'''<br> ❑ Central<br> ❑ Peripheral <br> ❑ Pleural lesion <br>'''Size''' <br>'''Lesion characteristics'''<br>  ❑ Margins (irregular/regular)<br>  ❑ Shape (spiculated/rounded)<br>'''Presence of cavitation'''<br>❑ Yes<br>❑ No<br>''' [[Lymphadenopathy|Type of adenopathy]]'''<br> ❑ Hiliar <br> ❑ Mediastinal <br></div>}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | |`|-| D01 | | | | | | | | D01=<div style="width: 15em; padding:1em;">'''[[Non small cell lung cancer staging|'''Diagnosis and Staging Assessment''']]'''</div>}}
{{familytree | | | |`|-| D01 | | | | | | | | D01=<div style="width: 15em; padding:1em;">'''[[Non small cell lung cancer staging|'''Diagnosis and Staging Assessment''']]'''</div>}}
Line 47: Line 47:
{{familytree | | | | | | X01 | | | | | | | X01=<div style="width: 17em; padding:1em;text-align:left">'''[[Non small cell lung cancer other diagnostic studies|'''Other Imaging or Diagnostic Modalities''']]'''<br>❑ Sputum cytology <br> ❑ Endobronchial ultrasound <br> ❑ Endoscopic ultrasound <br> ❑ Bronchoscopy <br> ❑ Mediastinoscopy <br> ❑ PET/CT </div>}}
{{familytree | | | | | | X01 | | | | | | | X01=<div style="width: 17em; padding:1em;text-align:left">'''[[Non small cell lung cancer other diagnostic studies|'''Other Imaging or Diagnostic Modalities''']]'''<br>❑ Sputum cytology <br> ❑ Endobronchial ultrasound <br> ❑ Endoscopic ultrasound <br> ❑ Bronchoscopy <br> ❑ Mediastinoscopy <br> ❑ PET/CT </div>}}
{{familytree | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | F01 | | | | | | | F01=<div style="width: 15em; padding:1em;">'''[[Non small cell lung cancer biopsy|Biopsy]]''' </div>}}
{{familytree | | | | | | F01 | | | | | | | F01=<div style="width: 15em; padding:1em;">'''[[Non small cell lung cancer other diagnostic studies|Biopsy]]''' </div>}}
{{familytree/end}}
{{familytree/end}}


Line 66: Line 66:
**For more information on MRI findings of non small cell lung cancer, [[Non small cell lung cancer MRI|click here]].
**For more information on MRI findings of non small cell lung cancer, [[Non small cell lung cancer MRI|click here]].


==Staging==
== Staging ==
The following is 2017 TNM classification of lung cancer.<ref>{{cite book | last =Mountain | first =CF | authorlink = | coauthors =Libshitz HI, Hermes KE | title =A Handbook for Staging, Imaging, and Lymph Node Classification | publisher =Charles P Young Company | date =2003 | url =http://www.ctsnet.org/book/mountain/index.html | accessdate =2007-09-01 }}</ref><ref name="Collins">{{cite journal | last = Collins | first = LG | coauthors = Haines C, Perkel R, Enck RE | title = Lung cancer: diagnosis and management | journal = American Family Physician | volume = 75 | issue = 1 | pages = 56–63 | publisher = American Academy of Family Physicians | date = Jan 2007 | url= http://www.aafp.org/afp/20070101/56.html | pmid =17225705 | accessdate =2007-08-10 }}</ref><ref name="HarmsKriegsmann2017">{{cite journal|last1=Harms|first1=A.|last2=Kriegsmann|first2=M.|last3=Fink|first3=L.|last4=Länger|first4=F.|last5=Warth|first5=A.|title=Die neue TNM-Klassifikation für Lungentumoren|journal=Der Pathologe|volume=38|issue=1|year=2017|pages=11–20|issn=0172-8113|doi=10.1007/s00292-017-0268-y}}</ref>


*Staging system classifications for non-small cell lung cancer include:
===T: Primary Tumor===
**American Joint Committee on Cancer (AJCC) staging system
{|
**International Union Against Cancer (UICC) staging system
===American Joint Committee on Cancer (AJCC) Staging===
*The table below summarizes the TNM staging system for the diagnosis of non-small cell lung cancer.<ref name="pmid20180029">{{cite journal |vauthors=Edge SB, Compton CC |title=The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM |journal=Ann. Surg. Oncol. |volume=17 |issue=6 |pages=1471–4 |date=June 2010 |pmid=20180029 |doi=10.1245/s10434-010-0985-4 |url=}}</ref>
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center"
| valign="top" |
|+
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|TNM}}
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Description}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |TX
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Description'''
| style="padding: 5px 5px; background: #F5F5F5;" |The primary [[tumour]] cannot be assessed, or there are [[malignant]] [[cell (biology)|cells]] in the [[sputum]] or [[bronchoalveolar lavage]] but not seen on imaging or [[bronchoscopy]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |TX || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Primary tumor cannot be assessed.<br> OR <br>Tumor is demonstrated by the presence of malignant cells in bronchial washings or [[sputum]], but is not visualized by imaging or [[bronchoscopy]].
| style="padding: 5px 5px; background: #F5F5F5;" |No evidence of primary tumor
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Tis
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | T0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is no evidence of primary tumor.
| style="padding: 5px 5px; background: #F5F5F5;" |[[Carcinoma in situ]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T1
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tis || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Carcinoma in situ
| style="padding: 5px 5px; background: #F5F5F5;" |Tumour less than 3 cm in its greatest dimension, surrounded by [[lung]] or visceral [[pleura]] and without bronchoscopic invasion into the main [[bronchus]].
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T2
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |The tumor has the following characteristics:
| style="padding: 5px 5px; background: #F5F5F5;" |A tumour with any of: More than 3 cm in greatest dimension; Extending into the main bronchus, but more than 2 cm distal to the [[Carina (anatomy)|carina]]; Obstructive [[pneumonitis]], but not involving the entire lung
* T1a: tumor ≤1 cm in the largest diameter.
 
* T1b: tumor> 1 cm, but ≤2 cm in the largest diameter.
* T1c: tumor> 2 cm, but ≤3 cm in the largest diameter.<br> AND <br>The tumor is surrounded by lung or [[visceral pleura]]<br> AND <br>The tumor does not extend to the main bronchus as demonstrated by the absence of bronchoscopic evidence of invasion more proximal than the lobar bronchus.
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T3
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |The tumor has the following characteristics:
| style="padding: 5px 5px; background: #F5F5F5;" |A tumour with any of: Invasion of the chest wall, [[Thoracic diaphragm|diaphragm]], [[mediastinum|mediastinal]] pleura, or parietal [[pericardium]]; Extending into the main bronchus, within 2 cm of the carina, but not involving the carina; Obstructive pneumonitis of the entire lung
* T2a: tumor> 3 cm, but ≤4 cm in the largest diameter.
* T2b: Tumor> 4 cm, but ≤5 cm in the largest diameter.<br>The tumor involves the main bronchus, 2 cm or more distal to the [[carina]]. <br> OR <br>The tumor invades the [[visceral pleura]]. <br> OR <br>There is evidence of [[atelectasis]] or obstructive [[pneumonitis]] that extends to the hilar region without the involvement of the entire lung.
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tumor > 5 cm, but ≤ 7 cm in size.
AND
 
It directly invades any of the following: [[chest wall]] (including superior sulcus tumors), [[diaphragm]], mediastinal pleura, parietal [[pericardium]].<br> OR <br>The tumor is localized in the main bronchus at a distance less than 2 cm distal to the [[carina]] but without the involvement of the [[carina]].<br> OR <br>There is evidence of associated [[atelectasis]] or obstructive [[pneumonitis]] of the entire lung.
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |T4
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tumor > 7 cm in size.
| style="padding: 5px 5px; background: #F5F5F5;" |A tumour with any of: Invasion of the mediastinum, [[heart]], great vessels, [[Vertebrate trachea|trachea]], [[oesophagus]], [[vertebra]], or carina; Separate tumour nodules in the same lobe; Malignant [[pleural effusion]]
The tumor invades any of the following: [[mediastinum]], [[heart]], great vessels, [[trachea]], [[esophagus]], [[vertebral body]], [[carina]]<br> OR <br>There is/are separate tumor nodule(s) in the same lobe. <br> OR
The tumor is associated with malignant [[pleural effusion]].
|}
 
===N:Regional Lymph Nodes===
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
| colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Regional Lymph Nodes}}
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Description'''
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |NX
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |NX || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |the regional [[lymph node]]s cannot be assessed.
| style="padding: 5px 5px; background: #F5F5F5;" |[[Lymph node]]s cannot be assessed
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |N0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is no evidence of regional lymph node metastasis.
| style="padding: 5px 5px; background: #F5F5F5;" |No lymph nodes involved
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |N1
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |[[Metastasis]] in [[Anatomical terms of location|ipsilateral]] peribronchial and/or [[Anatomical terms of location|ipsilateral]] [[Hilar lymphadenopathy|hilum]] or intrapulmonary [[Lymph node|lymph nodes]]
| style="padding: 5px 5px; background: #F5F5F5;" |[[Metastasis]] to [[ipsilateral]] peribronchial or ipsilateral hilar lymph nodes
N1a - A [[lymph node]] invasion.
 
N1b - > 1 [[lymph node]] affected.
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |N2
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is [[metastasis]] in ipsilateral [[Mediastinum|mediastinal]] and/or subcarinal [[Lymph node|lymph node(s).]]
| style="padding: 5px 5px; background: #F5F5F5;" |Metastasis to ipsilateral mediastinal or subcarinal lymph nodes
N2a1 - One lymph node infested without lymph node involvement of an N1-defined lymph node station.
 
N2a2 - One lymph node infested with a lymph node of an N1-defined lymph node station
 
N2b - > 1 lymph node affected
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is [[metastasis]] in [[Anatomical terms of location|contralateral]] [[Mediastinum|mediastinal]], contralateral [[Hilum|hilar]], [[Anatomical terms of location|ipsilateral]] or [[Anatomical terms of location|contralateral]] scalene, or supraclavicular [[Lymph node|lymph node(s).]]
|}
 
===M: Distant Metastasis===
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |N3
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Description'''
| style="padding: 5px 5px; background: #F5F5F5;" |Metastasis to any of: Ipsilateral supraclavicular lymph nodes; Ipsilateral scalene lymph nodes; [[Contralateral]] lymph nodes.
|- |-
| colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Distant Metastasis}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |MX
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |MX || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Distant metastasis cannot be assessed.
| style="padding: 5px 5px; background: #F5F5F5;" |Distant metastasis cannot be assessed
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |M0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is no evidence of distant [[metastasis]].
| style="padding: 5px 5px; background: #F5F5F5;" |No distant metastasis
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |M1
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is evidence of [[distant]] metastasis which includes the presence of separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).
| style="padding: 5px 5px; background: #F5F5F5;" |Distant metastasis is present
M1a - Tumor foci separated from the primary tumor in a contralateral lung lobe; Tumor with pleural metastases or malignant pleural or pericardial effusion
|}
 
M1b - Simple metastases in an organ


===International Union Against Cancer (UICC) Staging System===
M1c - Multiple metastases in one organ or one or more metastases in more than one organ


*The table below summarizes the TNM staging system for the diagnosis of non-small cell lung cancer.<ref name="urlwww.hoofdhalskanker.info">{{cite web |url=https://www.hoofdhalskanker.info/wpavl/wp-content/uploads/TNM-Classification-of-Malignant-Tumours-8th-edition.pdf |title=www.hoofdhalskanker.info |format= |work= |accessdate=}}</ref>
|}


{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center"
==Classification of Lung Cancer by Staging==
| valign="top" |
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|+
|-
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Stage}}
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Stage'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''N'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''M'''
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF| T}}
|-
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF| N}}
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Occult carcinoma''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |TX|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF| M}}
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage 0''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tis || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IA1''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1(mi)/T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IA2''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | '''Stage IA3'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="5" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="13" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIIA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Occult carcinoma
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |TX
| style="padding: 5px 5px; background: #F5F5F5;" |N0
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Stage 0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |Tis
| style="padding: 5px 5px; background: #F5F5F5;" |N0
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Stage IA
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |T1
| style="padding: 5px 5px; background: #F5F5F5;" |N0
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Stage IB
| rowspan="12" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIIB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |T2
| style="padding: 5px 5px; background: #F5F5F5;" |N0
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Stage IIA
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |T1
| style="padding: 5px 5px; background: #F5F5F5;" |N1
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" |Stage IIB
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |T2
| style="padding: 5px 5px; background: #F5F5F5;" |N1
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |T3
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |N0
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| rowspan="4" style="padding: 5px 5px; background: #DCDCDC;" |Stage IIIA
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |T1
| style="padding: 5px 5px; background: #F5F5F5;" |N2
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |T2
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |N2
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |T3
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |N1
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |T3
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |N2
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" |Stage IIIB
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |Any T
| style="padding: 5px 5px; background: #F5F5F5;" |N3
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |T4   
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |Any N
| style="padding: 5px 5px; background: #F5F5F5;" |M0
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" |Stage IV
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |Any T  
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Any N
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="padding: 5px 5px; background: #F5F5F5;" |M1
|-
| rowspan="2"  style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIIC'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="2" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IVA'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any T || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any N || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1a
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any T || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any N || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1b
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IVB'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any T || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any N || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1c
|}
|}


==References==
==References==

Latest revision as of 17:02, 22 February 2019

Non Small Cell Lung Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non Small Cell Lung Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Approach

Stage I
Stage II
Stage III
Stage IV
Metastatic Cancer

Medical Therapy

Chemotherapy
Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non small cell lung cancer diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non small cell lung cancer diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non small cell lung cancer diagnostic study of choice

CDC on Non small cell lung cancer diagnostic study of choice

Non small cell lung cancer diagnostic study of choice in the news

Blogs on Non small cell lung cancer diagnostic study of choice

Directions to Hospitals Treating Non small cell carcinoma of the lung

Risk calculators and risk factors for Non small cell lung cancer diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2], Furqan M M. M.B.B.S[3]

Overview

Chest X-Ray is the initial study performed when non-small cell lung cancer is suspected. Contrast-enhanced computed tomography of the chest, neck and abdomen is the best next step in diagnosing non-small cell lung cancer. Endobronchial ultrasound is a first-line diagnostic modality for the mediastinal staging of the non-small cell lung cancer. The lung biopsy is the gold standard for the diagnosis of the non-small cell lung cancer. The lung biopsy is used to confirm the diagnosis of non small cell lung cancer and identify the histopathological subtype to plan for the treatment.

Diagnostic Study of Choice

Diagnostic approach to the non small cell lung cancer

Non small cell cancer of the lung is diagnosed by the following approach:[1][2]

Gold standard

  • Lung biopsy is the gold standard test for the diagnosis of non-small cell lung cancer.[4]
  • The diagnostic result of lung biopsy is confirmatory of non-small cell lung cancer and depends on the histopathological type of cancer. Click here to view the biopsy findings of the subtypes.

Evaluation Algorithm for Suspected Non-Small Cell Lung Cancer

The algorithm below summarizes the initial imaging approach for patients with suspected non-small cell lung cancer.


 
 
 
 
 
Imaging approach
❑ Suspected lung cancer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest X Ray normal?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enhanced Computed Tomography (ECT), includes:
❑ Thorax
❑ Upper Abdomen
❑ Low Neck
 
 
 
Manage and observe
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging evaluation
 
 
 
 
 
 
 
 
 
 
 
 
 
Location
❑ Central
❑ Peripheral
❑ Pleural lesion
Size
Lesion characteristics
❑ Margins (irregular/regular)
❑ Shape (spiculated/rounded)
Presence of cavitation
❑ Yes
❑ No
Type of adenopathy
❑ Hiliar
❑ Mediastinal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Imaging or Diagnostic Modalities
❑ Sputum cytology
❑ Endobronchial ultrasound
❑ Endoscopic ultrasound
❑ Bronchoscopy
❑ Mediastinoscopy
❑ PET/CT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diagnostic modality for staging

Staging of cancer and extent of metastasis can be diagnosed by various methods.[1][2][5]

  • Endoscopic ultrasound:
    • First-line diagnostic modality for mediastinal staging.
    • For more information on ultrasound findings of non small cell lung cancer, click here.
  • CT scan:
    • Contrast-enhanced CT scan is used to diagnose distant metastasis to liver, adrenal gland, brain or other organs.
    • For more information on CT scan findings of non small cell lung cancer, click here.
  • PET/CT scan:
    • PET scan is used to detect non small cell lung cancer in the early stage, look for possible metastasis to liver, adrenal gland or other organs.
    • PET scan cannot be used to diagnose metastasis to the brain because brain cells are normally illuminated in PET scan due to high glucose uptake.
    • For more information on PET scan findings of non small cell lung cancer, click here.
  • MRI scan:
    • MRI scan is most often used to look for possible metastasis to the brain or spinal cord.
    • For more information on MRI findings of non small cell lung cancer, click here.

Staging

The following is 2017 TNM classification of lung cancer.[6][7][8]

T: Primary Tumor

T Description
TX Primary tumor cannot be assessed.
OR
Tumor is demonstrated by the presence of malignant cells in bronchial washings or sputum, but is not visualized by imaging or bronchoscopy.
T0 There is no evidence of primary tumor.
Tis Carcinoma in situ
T1 The tumor has the following characteristics:
  • T1a: tumor ≤1 cm in the largest diameter.
  • T1b: tumor> 1 cm, but ≤2 cm in the largest diameter.
  • T1c: tumor> 2 cm, but ≤3 cm in the largest diameter.
    AND
    The tumor is surrounded by lung or visceral pleura
    AND
    The tumor does not extend to the main bronchus as demonstrated by the absence of bronchoscopic evidence of invasion more proximal than the lobar bronchus.
T2 The tumor has the following characteristics:
  • T2a: tumor> 3 cm, but ≤4 cm in the largest diameter.
  • T2b: Tumor> 4 cm, but ≤5 cm in the largest diameter.
    The tumor involves the main bronchus, 2 cm or more distal to the carina.
    OR
    The tumor invades the visceral pleura.
    OR
    There is evidence of atelectasis or obstructive pneumonitis that extends to the hilar region without the involvement of the entire lung.
T3 Tumor > 5 cm, but ≤ 7 cm in size.

AND

It directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium.
OR
The tumor is localized in the main bronchus at a distance less than 2 cm distal to the carina but without the involvement of the carina.
OR
There is evidence of associated atelectasis or obstructive pneumonitis of the entire lung.

T4 Tumor > 7 cm in size.

The tumor invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina
OR
There is/are separate tumor nodule(s) in the same lobe.
OR The tumor is associated with malignant pleural effusion.

N:Regional Lymph Nodes

T Description
NX the regional lymph nodes cannot be assessed.
N0 There is no evidence of regional lymph node metastasis.
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilum or intrapulmonary lymph nodes

N1a - A lymph node invasion.

N1b - > 1 lymph node affected.

N2 There is metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).

N2a1 - One lymph node infested without lymph node involvement of an N1-defined lymph node station.

N2a2 - One lymph node infested with a lymph node of an N1-defined lymph node station

N2b - > 1 lymph node affected

N3 There is metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).

M: Distant Metastasis

T Description
MX Distant metastasis cannot be assessed.
M0 There is no evidence of distant metastasis.
M1 There is evidence of distant metastasis which includes the presence of separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).

M1a - Tumor foci separated from the primary tumor in a contralateral lung lobe; Tumor with pleural metastases or malignant pleural or pericardial effusion

M1b - Simple metastases in an organ

M1c - Multiple metastases in one organ or one or more metastases in more than one organ

Classification of Lung Cancer by Staging

Stage T N M
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA1 T1(mi)/T1a N0 M0
Stage IA2 T1b N0 M0
Stage IA3 T1c N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
Stage IIB T1a N1 M0
T1c N1 M0
T2a N1 M0
T2b N1 M0
T3 N0 M0
Stage IIIA T1a N2 M0
T1b N2 M0
T1c N2 M0
T2a N2 M0
T2b N2 M0
T1a N2 M0
T1b N2 M0
T1c N2 M0
T2a N2 M0
T2b N2 M0
T3 N1 M0
T4 N0 M0
T4 N1 M0
Stage IIIB T1a N3 M0
T1b N3 M0
T1c N3 M0
T2a N3 M0
T2b N3 M0
T1a N3 M0
T1b N3 M0
T1c N3 M0
T2a N3 M0
T2b N3 M0
T3 N2 M0
T4 N2 M0
Stage IIIC T3 N3 M0
T4 N3 M0
Stage IVA Any T Any N M1a
Any T Any N M1b
Stage IVB Any T Any N M1c


References

  1. 1.0 1.1 National Collaborating Centre for Cancer (UK) (2011 Apr). "The Diagnosis and Treatment of Lung Cancer (Update)" (No. 121). PMID 22855970. Vancouver style error: initials (help); Check date values in: |date= (help)
  2. 2.0 2.1 Purandare, NilenduC; Rangarajan, Venkatesh (2015). "Imaging of lung cancer: Implications on staging and management". Indian Journal of Radiology and Imaging. 25 (2): 109. doi:10.4103/0971-3026.155831. ISSN 0971-3026.
  3. Lee Y, Lee HJ, Kim YT, Kang CH, Goo JM, Park CM, Paeng JC, Chung DH, Jeon YK (2013). "Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival". Korean J Radiol. 14 (2): 375–83. doi:10.3348/kjr.2013.14.2.375. PMC 3590355. PMID 23483676.
  4. Kinsey CM, Arenberg DA (March 2014). "Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging". Am. J. Respir. Crit. Care Med. 189 (6): 640–9. doi:10.1164/rccm.201311-2007CI. PMID 24484269.
  5. "Tests for Non-Small Cell Lung Cancer".
  6. Mountain, CF (2003). A Handbook for Staging, Imaging, and Lymph Node Classification. Charles P Young Company. Retrieved 2007-09-01. Unknown parameter |coauthors= ignored (help)
  7. Collins, LG (Jan 2007). "Lung cancer: diagnosis and management". American Family Physician. American Academy of Family Physicians. 75 (1): 56–63. PMID 17225705. Retrieved 2007-08-10. Unknown parameter |coauthors= ignored (help)
  8. Harms, A.; Kriegsmann, M.; Fink, L.; Länger, F.; Warth, A. (2017). "Die neue TNM-Klassifikation für Lungentumoren". Der Pathologe. 38 (1): 11–20. doi:10.1007/s00292-017-0268-y. ISSN 0172-8113.

Template:WH Template:WS